Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

[News]

The U.S. Food and Drug Administration approved Xgeva (denosumab) on Thursday to help prevent skeletal-related events (SREs) in patients with cancer that has spread (metastasized) and damaged the bone. Skeletal-related events include bone fractures from cancer and bone pain requiring radiation.

More... (http://www.news-medical.net/news/20101119/Xgeva-receives-FDA-approval-for-prevention-of-SREs-in-patients-with-bone-metastases.aspx)